secwatch.observer — SEC 8-K summary
======================================

Issuer:     Penumbra Inc (PEN)
CIK:        0001321732
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001321732-24-000116
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Penumbra Q3 revenue $301M (+11.1% YoY); U.S. thrombectomy up 21.2%; raises segment guidance
--------------------------------------------------------------------------------

- Revenue $301.0M, +11.1% YoY; net income $29.5M; adjusted EBITDA $56.7M (18.8% margin).
- U.S. thrombectomy revenue $162.1M, +21.2% YoY; VTE franchise grew 32% vs Q3 2023.
- GAAP operating income $35.4M vs $12.6M in Q3 2023; non-GAAP operating income $40.3M.
- Full-year 2024 revenue reaffirmed $1.18-1.20B; U.S. thrombectomy growth expectation raised to 24-25% from 23-25%.
- Wind down of Immersive Healthcare incurred $5M in one-time expenses during Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321732/000132173224000116/0001321732-24-000116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321732/000132173224000116/pen-20241030.htm
  HTML page:      https://secwatch.observer/filing/0001321732-24-000116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer